We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Stereotactic Laser Ablation for Temporal Lobe Epilepsy (SLATE)

This study is currently recruiting participants.
Verified October 2017 by Medtronic Surgical Technologies ( Medtronic Navigation, Inc. )
ClinicalTrials.gov Identifier:
First Posted: July 26, 2016
Last Update Posted: October 25, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Medtronic Surgical Technologies ( Medtronic Navigation, Inc. )
The study is designed to evaluate the safety and efficacy of the Visualase MRI-guided laser ablation system for mesial temporal epilepsy (MTLE).

Condition Intervention
Temporal Lobe Epilepsy Device: Visualase MRI-Guided Laser Ablation

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Stereotactic Laser Ablation for Temporal Lobe Epilepsy

Resource links provided by NLM:

Further study details as provided by Medtronic Surgical Technologies ( Medtronic Navigation, Inc. ):

Primary Outcome Measures:
  • Incidence of qualifying adverse events [ Time Frame: 12 months ]
  • Seizure freedom, defined as Engel Classification of Postoperative Outcome Class I [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • Seizure freedom compared to historical controls [ Time Frame: 12 months ]
  • Seizure freedom, including subjects retreated with Visualase [ Time Frame: 12 months ]
  • Change in Boston Naming Test scores [ Time Frame: Baseline and 12 months ]
  • Change in Rey Auditory Verbal Learning Test scores [ Time Frame: Baseline and 12 months ]
  • Change in Short Form-36 (SF-36) Health Survey scores [ Time Frame: Baseline and 12 months ]
  • Change in Quality of Life in Epilepsy (QOLIE-31) scores [ Time Frame: Baseline and 12 months ]

Estimated Enrollment: 120
Study Start Date: November 2016
Estimated Study Completion Date: October 2020
Estimated Primary Completion Date: October 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment
Visualase MRI-guided laser ablation procedure
Device: Visualase MRI-Guided Laser Ablation
All subjects will undergo MRI-guided laser ablation of the amygdala and hippocampus with the Visualase System.
Other Names:
  • Visualase System
  • Visualase procedure
  • Laser interstitial thermal therapy
  • Stereotactic laser ablation

Detailed Description:

The purpose of the study is to evaluate the safety and efficacy of the Visualase MRI-guided laser ablation system for necrotization or coagulation of epileptogenic foci in patients with intractable mesial temporal lobe epilepsy.

The study will include approximately 120 adult patients with drug-resistant MTLE treated at selected epilepsy centers across the United States. After the Visualase procedure, patients will be followed for 12 months and evaluated for freedom from seizures, quality of life, adverse events, and neuropsychological outcomes.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • History of drug-resistant mesial temporal lobe epilepsy (MTLE)
  • If the subject has a vagus nerve stimulator (VNS), must have failed to achieve sustained seizure freedom with the VNS implanted for at least 6 months
  • On stable antiepileptic drugs (AEDs) (and/or stable VNS setting, if applicable) and compliant with medication use
  • An average of at least 1 complex partial or secondarily generalized seizure compatible with MTLE per month
  • Seizure symptoms and/or auras compatible with MTLE
  • Video EEG shows evidence of seizures from one temporal lobe consistent with MTLE
  • MRI has evidence consistent with mesial temporal lobe sclerosis
  • Willing and able to remain on stable AEDs (and stable VNS setting, if applicable) for 12 months following the Visualase procedure
  • Willing and able to comply with protocol requirements
  • Able to complete study assessments in English or Spanish language

Exclusion Criteria:

  • Unwilling or unable to sign the study informed consent form
  • Pregnant or intends to become pregnant during the course of the study
  • Currently implanted with a device contraindicating MRI
  • Progressive brain lesions and/or tumors not associated with epileptic disease state
  • History of previous intracranial surgery for treatment of epileptic seizures
  • Persistent extra-temporal or predominant contralateral focal interictal spikes or slowing, or generalized interictal spikes on EEG
  • Seizures with contralateral or extra-temporal ictal onset on EEG
  • Aura and/or ictal behavior suggest an extra-temporal focus
  • MRI evidence of epileptogenic, extra-temporal lesions, dual pathology in the temporal lobe, or contralateral hippocampal MRI increased signal and/or loss of architecture
  • If additional testing has been performed, results are discordant with the seizure focus scheduled for ablation
  • Non-compliance with AED requirements
  • IQ < 70
  • Dementia or other progressive neurological disease
  • Unstable major psychiatric illness, psychogenic non-epileptic seizures, or medical illness that would contraindicate the Visualase procedure or affect the neuropsychological assessments
  • Participation in other research that may potentially interfere with SLATE endpoint(s)
  • Allergy to gadolinium
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02844465

Contact: Guy Alvarez, PhD rs.slatestudy@medtronic.com

United States, California
Stanford University Recruiting
Palo Alto, California, United States, 94305
Contact: Bharati Sanjanwala, MS    650-721-2830    bharatis@stanford.edu   
Contact: Anthony Bet    650-683-5823    abet0915@stanford.edu   
Principal Investigator: Casey Halpern, MD         
University of California, San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: Felicia Kuo       felicia.kuo@ucsf.edu   
Principal Investigator: Robert Knowlton, MD         
United States, Colorado
University of Colorado Anschutz Medical Campus Recruiting
Aurora, Colorado, United States, 80045
Contact: Pamela David Gerecht, PhD    303-724-4134    Pamela.DavidGerecht@ucdenver.edu   
Principal Investigator: Aviva Abosch, MD, PhD         
United States, Florida
University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Letitia Fisher    305-243-7108    lfisher@med.miami.edu   
Principal Investigator: Jonathan Jagid, MD         
United States, Georgia
Emory University Recruiting
Atlanta, Georgia, United States, 30322
Contact: Yvan Bamps, PhD    404-778-7673    yvan.bamps@emory.edu   
Principal Investigator: John T. Willie, MD, PhD         
United States, Indiana
Indiana University Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Abigail Klaehn, RN, BSN    317-963-7440    aklaehn@iupui.edu   
Principal Investigator: Vicenta Salanova, MD         
United States, Maryland
Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21287
Contact: Tony Stanfield    415-502-0965    astanfi1@jhmi.edu   
Contact: Joon-Yi Kang, MD    410-955-2822      
Principal Investigator: Joon-Yi Kang, MD         
United States, Michigan
Henry Ford Health System Recruiting
Detroit, Michigan, United States, 48202
Contact: Lisa Scarpace    313-916-2360    LSCARPA1@hfhs.org   
Principal Investigator: Jason Schwalb, MD         
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Karla Crockett    507-538-9140    crockett.karla@mayo.edu   
Principal Investigator: Jamie Van Gompel, MD         
United States, New Jersey
Rutgers University - Robert Wood Johnson Medical School Recruiting
New Brunswick, New Jersey, United States, 08901
Contact: Asha Cilly, MSN    732-235-7342    ac1659@rwjms.rutgers.edu   
Principal Investigator: Stephen Wong, MD         
United States, New York
Northwell Health Recruiting
Great Neck, New York, United States, 11021
Contact: Connie Lau    516-325-7022    clau@northwell.edu   
Principal Investigator: Ashesh D Mehta, MD, PhD         
Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Gail Iodice    212-305-1038    gd2023@cumc.columbia.edu   
Principal Investigator: Guy M. McKhann II, MD         
United States, North Carolina
Wake Forest Baptist Health Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Jessica P. Dimos    336-716-8694    jdimos@wakehealth.edu   
Principal Investigator: Gautam Popli, MD         
United States, Pennsylvania
Thomas Jefferson University Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Leah Shabo    215-503-3213    Leah.Shabo@jefferson.edu   
Principal Investigator: Michael Sperling, MD         
United States, Washington
University of Washington Harborview Recruiting
Seattle, Washington, United States, 98104
Contact: Gina DeNoble, MS    206-744-3624    gdenoble@uw.edu   
Principal Investigator: John W. Miller, MD, PhD         
Sponsors and Collaborators
Medtronic Navigation, Inc.
Principal Investigator: Robert Gross, MD, PhD Emory University
Principal Investigator: Michael Sperling, MD Thomas Jefferson University
  More Information

Responsible Party: Medtronic Navigation, Inc.
ClinicalTrials.gov Identifier: NCT02844465     History of Changes
Other Study ID Numbers: CS-05000
First Submitted: July 15, 2016
First Posted: July 26, 2016
Last Update Posted: October 25, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is not a plan to share individual participant data, but aggregate data for all primary and secondary endpoints will be shared.

Keywords provided by Medtronic Surgical Technologies ( Medtronic Navigation, Inc. ):
laser ablation
laser interstitial thermal therapy

Additional relevant MeSH terms:
Epilepsy, Temporal Lobe
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Epilepsies, Partial